



**International Journal of Biology, Pharmacy  
and Allied Sciences (IJBPAS)**

*'A Bridge Between Laboratory and Reader'*

[www.jibpas.com](http://www.jibpas.com)

---

---

**UV AND RP-HPLC METHOD DEVELOPMENT AND VALIDATION  
FOR THE ESTIMATION OF PIRFENIDONE IN MARKETED  
FORMULATION**

**SUNITHA N<sup>\*1</sup>, AMMU S<sup>2</sup> AND THANGABALAN B<sup>3</sup>**

**1:** Associate Professor

**2:** Student

**3:** Professor

SIMS College of Pharmacy, Mangaldas nagar, Guntur, Andhra Pradesh

**\*Corresponding Author: Dr. N. Sunitha: E Mail: [suniadikarb4@gmail.com](mailto:suniadikarb4@gmail.com)**

Received 26<sup>th</sup> May 2023; Revised 27<sup>th</sup> July 2023; Accepted 6<sup>th</sup> Sept. 2023; Available online 1<sup>st</sup> May 2024

<https://doi.org/10.31032/IJBPAS/2024/13.5.8059>

**ABSTRACT**

The UV Spectrophotometric method, with water was proved to be simple, precise accurate and sensitive from the results of the validation and it is suitable method for the estimation of pirfenidone in its pharmaceutical dosage forms.

A RP-HPLC method was developed using the mobile phase of 50:48.5:1.5 %v/v methanol and water and tri ethylamine. The run time of the developed method was six minutes, which reduces the solvent usage. The chromatographic conditions use ambient temperature which can yield accurate, precise results in the range of 25-35 °C. The results of the validation parameters showed that the method is accurate and precise. Finally, it can be concluded that the methods for quantitation of pirfenidone by RP-HPLC Method in its pharmaceutical dosage forms can be applied for the routine analysis because of simplicity, accuracy, and preciseness.

**Keywords: UV Spectrophotometric method, RP-HPLC, Pirfenidone**

## INTRODUCTION:

Pirfenidone is a novel antifibrotic drug approved for mild to moderate idiopathic pulmonary fibrosis as orphan drug in Japan and Europe. Pirfenidone is the only drug which has been approved for the treatment of IPF. Pirfenidone is a small non-peptide molecule of low molecular weight (185.2 daltons) with the chemical name of 5-methyl-1-phenyl-2-(1H)-pyridone [1-22].

## MATERIALS AND METHODS

### Drug Profile

#### Pirfenidone




Figure 1: Structure of Pirfenidone

**Molecular Formula:** C<sub>12</sub>H<sub>11</sub>NO.

**Molecular Weight:** 185.2 Daltons.

**IUPAC name:** 5-methyl-1-phenyl-1,2-dihydropyridin-2-one.

**Color:** White solid.

**Melting point:** 96-97°C.

**Boiling point:** 329.1±15°C.

**Storage:** Stored in room temperature.

**Solubility:** Soluble in water, methanol and acetonitrile.

**Uses:** Pirfenidone is a novel compound with demonstrated Anti-inflammatory, Anti-fibrotic & Antioxidant activities

that makes it a suitable candidate molecule for managing Idiopathic pulmonary fibrosis.

### Determination of wavelength of maximum absorbance ( $\lambda_{max}$ ) of pirfenidone:

The dilution was obtained to the concentration of 10  $\mu$ g / ml for pirfenidone solutions. The solution was scanned in UV range (200-400nm) in 10 mm Quartz cell against Double distilled water blank. The study of spectrum revealed that pirfenidone shows a well-defined  $\lambda_{max}$  at 312 nm.

### Preparation of standard solutions:

Standard stock solution containing 1000  $\mu$ g/ml was prepared, 10mg of pirfenidone was accurately weighed and transferred into 10 ml volumetric flask and made up to the mark with Double distilled water, standard solutions were prepared in the concentration range of 1 – 10  $\mu$ g / ml by further dilution with water.

### Preparation of standard calibration curve:

The absorbance's of the standard solutions in water at 1-10  $\mu$ g / ml range was measured at 312 nm. Standard calibration curve was prepared by plotting maximum absorbance ( $\lambda_{max}$ ) versus concentration.

Linearity was studied using a regression equation.

### **Estimation of pirfenidone in marketed formulation:**

#### **Preparation of pirfenidone test solution**

A stock solution (1000  $\mu\text{g} / \text{ml}$ ) was prepared by taking 20 tablets, crushed, powdered; weight equivalent to 1000  $\mu\text{g} / \text{ml}$  of standard pirfenidone solution was taken and dissolved in a 10 ml volumetric flask using Double distilled water. The solution sonicated for 20 min and placed undisturbed overnight, again sonicated for 15 minutes and filtered through Whatman filter paper. From the clear test stock solution, pipette out 1 ml and make up to 10 ml with Double distilled water (100  $\mu\text{g} / \text{ml}$ ), From that pipette out 1 ml and make up to 10 ml with Double distilled water to obtain a concentration of 10  $\mu\text{g}/\text{ml}$  and serial dilutions were prepared (1  $\mu\text{g} / \text{ml}$ , 3  $\mu\text{g} / \text{ml}$ , 5  $\mu\text{g} / \text{ml}$ , 7  $\mu\text{g} / \text{ml}$ , 9  $\mu\text{g} / \text{ml}$ )

### **Method Validation**

#### **Linearity**

Prepared in 6 spikes of 1-10  $\mu\text{g} / \text{ml}$  then analyze by spectrophotometrically. A graph of Concentration Vs Absorbance was plotted and correlation coefficient was calculated.

#### **Accuracy (% Recovery)**

The accuracy of the analytical method was assessed by determination of recovery for three concentrations corresponding to 50, 100 and 150 % of test solution concentration. For each concentration, three sets were prepared. The mean recovery of pirfenidone was reported.

### **Precision**

#### **Preparation of standard stock solution:**

About 10 mg of pirfenidone was taken in to 10 ml volumetric flask, and diluted up to 10 ml with diluent

**A. Repeatability-** Repeatability expresses the precision under the same operating conditions over a short interval of time. It means the study was performed morning and evening for all concentrations (1-10  $\mu\text{g} / \text{ml}$  solution) 6 times and % RSD was calculated.

**B. Intermediate precision-** Intermediate precision expresses within - laboratories variations: different days, different analysts, different equipment, etc. It means the study was performed different analyst (analyst -1 and analyst -2) for all concentrations (1 -10  $\mu\text{g} / \text{ml}$  solution) 6 times and % RSD was calculated.

**C. Reproducibility-** Reproducibility expresses the precision between laboratories (collaborative studies, usually applied to the standardization of

methodology). It means the study was performed today and tomorrow for all concentrations (1-10  $\mu\text{g} / \text{ml}$  solution) 6 times and % RSD was calculated.

### **Robustness**

The estimation of pirfenidone was performed at different environmental conditions (room temp at 29°C and elevated temp 35°C).

### **Ruggedness**

The ruggedness is to express within-laboratories variations: different days, different analysts, different equipment, etc

### **Detection Limit & Quantitation Limit**

LOD and LOQ were based on the third approach and were calculated according to the  $3.3\sigma/S$  and  $10\sigma/S$  respectively; where  $\sigma$  is the standard deviation of y-intercepts of regression lines and s is the slope of the calibration curve.

### **RP-HPLC Method**

#### **Preparation of Standard Stock Solution:**

An accurately weighed quantity of (10 mg) pirfenidone was transferred to a 10mL volumetric flask, dissolved and diluted to the mark with Methanol : Water : Triethylamine (50:48.5:1.5 %v/v) to obtain standard stock solution of 1000 $\mu\text{g}/\text{ml}$ .

#### **Preparation of mobile phase:**

Take 50 ml of methanol was transferred to 100 ml of volumetric flask then add 48.5 ml of double distilled water and add 1.5 ml of tri ethylamine then sonicate it for 1hr and filter the mobile phase (50:48.5:1.5 v/v).

#### **Preparation of Pirfenidone test solution:**

A stock solution (1000  $\mu\text{g}/\text{ml}$ ) was prepared by taking 20 tablets , weight equivalent to (1000  $\mu\text{g}/\text{ml}$ ) of standard Gallic acid solution was taken and dissolved in a 10 ml volumetric flask using Methanol : Water : Triethylamine (50 : 48.5:1.5 %v/v). The solution sonicated for 20 min and placed undisturbed overnight, again sonicated for 15 minutes and filtered through Whattman filter paper. From the clear test stock solution, pipette out 1 ml and make up to 10 ml with solvent (100  $\mu\text{g}/\text{mL}$ ), From that pipette out 0.5, 1, 1.5, 2 & 2.5 ml and make up to 10 ml with solvent to obtain a concentration of 5-25 $\mu\text{g}/\text{ml}$ .

#### **Method validation**

##### **Specificity**

Specificity include impurities, degradants, matrix, etc.

##### **Linearity**

Accurately weighed 10 mg of pirfenidone transfer to 10 ml of volumetric

flask. Admade up the volume with Methanol : Water : Triethylamine and sonicate it for 10min (1000 µg /ml). These are prepared in 6 spikes of 5-25 µg / ml then analyze by Chromatography. A graph of concentration Vs peak area was plotted and correlation coefficient was calculated.

#### **Accuracy (% Recovery)**

The accuracy of the method was determined by calculating the recovery of Pirfenidone by the standard addition method. The accuracy of the analytical method was assessed by determination of recovery for three concentrations corresponding to 50,100 and 150 % of test solution concentration. For each concentration, three sets were prepared. The mean recovery of Pirfenidone was reported.

#### **Preparation of standard stock solution:**

About 10 mg of Pirfenidone was taken in to 10 ml volumetric flask, and diluted up to 10 ml with diluent (1000 µg / ml) from these stock solution prepared 5-25 µg /ml solution.

#### **Preparation of 50% (30 µg /ml) solution:**

Taken 2 ml solution from 20 µg / ml sample solution and 1ml solution from 1 µg/ml standard solution into 10 ml volumetric flask, made up to the volume

with diluent and Peak area of these solutions was determined.

#### **Preparation of 100% (40 µg/ml) solution:**

Taken 2 ml solution from 20 µg/ml sample solution and 20 ml solution from 20 µg/ml standard solution into 10 ml volumetric flask.

#### **Preparation of 150% (50 µg/ml) solution:**

Taken 2ml solution from 20 µg/ml sample solution and 3ml solution from 30 µg/ml standard solution into 10 ml volumetric flask, made up to the volume with diluents.

#### **Precision**

The degree of reproducible results produced by a sample at different conditions **Preparation of standard stock solution:**

About 10 mg of Pirfenidone was taken in to 10 ml volumetric flask, and diluted up to 10 ml with diluent (1000 µg /ml) from these stock solution prepare 5-25 µg /ml solution.

**A. Repeatability** - Repeatability expresses the precision under the same operating conditions over a short interval of time. It means the study was performed morning and evening for all

concentrations (5-25  $\mu\text{g/ml}$  solution) 6 times and % RSD was calculated.

**B. Intermediate precision** - Intermediate precision expresses within-laboratories variations: different days, different analysts, different equipment, etc.

**C. Reproducibility** - Reproducibility expresses the precision between laboratories 6 times and % RSD was calculated.

### Robustness

The estimation of Pirfenidone was performed at different environmental conditions (room temp at  $29^\circ\text{C}$  and elevated temp  $35^\circ\text{C}$ ).

### Ruggedness

The ruggedness is to express within-laboratories variations: different days, different analysts, different equipment, etc

### Detection Limit & Quantitation Limit

The LOD and LOQ were based on the third approach and were calculated according to the  $3.3\sigma/S$  and  $10\sigma/S$  respectively; where  $\sigma$  is the standard deviation of y-intercepts of regression lines and  $s$  is the slope of the calibration curve.

## RESULTS AND DISCUSSION

The  $\lambda_{\text{max}}$  of pirfenidone was found to be 312 nm (Figure 2).




Figure 2: Spectrum of pirfenidone in water at 312 nm

### Selection of suitable wavelength



Figure 3:  $\lambda_{\text{max}}$  of pirfenidone

Table 1: Standard Graph Values

S.no	Concentration(µg/ml)	Absorbance(nm)
1	1	0.0333
2	3	0.1156
3	5	0.1998
4	7	0.2880
5	9	0.3776
6	10	0.4113




Figure 4: Calibration curve of Pirfenidone

Assay

Table 2: Assay Results

S. No.	Conc. (µg/ml)	Standard Absorbance(nm)	Test Absorbance(nm)	Amount Found	%Purity
1	5µg/ml	0.1998	0.199	262.9mg	98%

Spectroscopic Method Validation of Pirfenidone

Table 3: Linearity values

S. No.	Conc. ((µg/ml)	Absorbance (Mean, N=6)	Standard Deviation	%RSD
1	1	0.0333	0.0005	1.9
2	3	0.1156	0.0016	1.3
3	5	0.1998	0.0032	1.8
4	7	0.2880	0.0050	1.8
5	9	0.3776	0.0049	1.3
6	10	0.4113	0.0079	1.7




Figure 5: linearity graph (1-10µg/ml)

Table 4: Precision results

Precision	Repeatability		Reproducibility		Intermediate Precision		
	Morning	Evening	Day 1	Day 2	Analyst 1	Analyst 2	
Absorbance at 3µg/ml	S1	0.1162	0.1150	0.1162	0.1153	0.1162	0.1153
	S2	0.1179	0.1175	0.1179	0.1177	0.1179	0.1195
	S3	0.1141	0.1141	0.1141	0.1141	0.1141	0.1168
	S4	0.1161	0.1165	0.1161	0.1168	0.1161	0.1171
	S5	0.1165	0.1163	0.1165	0.1161	0.1165	0.1162
	S6	0.1169	0.1170	0.1169	0.1174	0.1169	0.1188
Mean	0.1162	0.1160	0.1162	0.1174	0.1162	0.11728333	
SD	0.0012528	0.00127854	0.0012528	0.00136186	0.0012528	0.00158672	
RSD	0.0107742	0.01101557	0.0107742	0.01171662	0.0107742	0.01352891	
%RSD	1.07%	1.101557296%	1.07%	1.17%	1.07%	1.35%	

Table 5: Accuracy results

Recovery Level	Test (initial amount)	Standard (amount added)	Absorbance			Mean	%Recovery
			S1	S2	S3		
50%	5ml	2.5ml	0.297	0.295	0.296	0.296	102%
100%	5ml	5ml	0.396	0.398	0.397	0.397	99%
150%	5ml	7.5ml	0.498	0.501	0.499	0.499	98%

Table 6: Robustness results

Robustness		At Room Temperature (25°C)		Elevated Temperature (29°C)	
Absorbance at 3µg/ml	S1	0.3572		0.3612	
	S2	0.3658		0.3701	
	S3	0.3589		0.3611	
	S4	0.3661		0.3689	
	S5	0.3655		0.3722	
	S6	0.3589		0.3665	
Mean	0.36206667		0.36666667		
SD	0.00414085		0.00465389		
RSD	0.01143672		0.01269242		
%RSD	1.14%		1.26%		

Table 7: Ruggedness results

Ruggedness		Analyst 1	Analyst 2
Absorbance at 3µg/ml	S1	0.1163	0.1153
	S2	0.1189	0.1195
	S3	0.1175	0.1168
	S4	0.1181	0.1171
	S5	0.1172	0.1162
	S6	0.1182	0.1188
Mean	0.1177		0.1172833
SD	0.00090554		0.00158672
RSD	0.0076		0.0135
%RSD	0.76%		1.35%

Table 8: LOD and LOQ

Limit of Detection	Limit of Quantification
0.242µg/ml	0.733µg/ml

### Chromatographic conditions:

Table 9: Optimized chromatographic conditions:

Column	Flowrosil C <sub>18</sub> column with 5 µm (Dimension)
Mobile phase	Methanol:water:triethylamine(50:48.5:1.5)%v/v
Flow rate	1ml/min
Temperature	Ambient
Run time	7min
Detection wavelength	312nm
Injection volume	10µl
Mode of operation	Isocratic elution




Figure 6: Optimized Chromatogram for Pirfenidone

Table 10: Chromatogram results for optimized method

Mobile phase	Methanol:water:tri ethylamine(50:48.5:1.5)%v/v)
Stationary phase	Flowrosil C <sub>18</sub> column with 5 μm (Dimension)
Wavelength	312nm
Run time	7min
Flow rate	1ml/min
Injection volume	10μg/ml
Mode of operation	Isocratic elution
Temperature	Ambient

Calibration curve




Figure 7: Calibration curve for Pirfenidone

Table 11: Assay Results

S. No.	Concentration (μg/ml)	Standard peak area (Mean±SD), n=3	Test peak area (Mean±SD), n=3	Amount of Pirfenidone found in mg(n=3)	Mean % recovery of Pirfenidone
1	20μg/ml	36060	35560	19.848	99.24




Figure 8: Chromatogram for 20 (µg/ml) Assay

Table 12: Chromatogram results for 20 (µg/ml) Assay

S. No.	Drug Name	Retention time(min)	Peak area	Theoretical plates	Tailing factor
1	pirfenidone	4.82	35560	5110.60	1.72




Figure 9: Chromatogram for (20 µg/ml) Standard

Table 13: Chromatogram results for (20µg/ml) standard

S. No.	Drug Name	Retention time(min)	Peak area	Theoretical plates	Tailing factor
1	pirfenidone	4.9	36060	5900.78	1.85

**Validation**

**Specificity**

Peaks of other marker were not found at retention time of 4.97 min.

**Blank:**



Figure 10: Blank injection chromatogram for specificity

Standard:




Figure 11: Chromatogram of Standard Pirfenidone

Sample:




Figure 12: Chromatogram of Test Pirfenidone

Linearity 5 µg/ml




Figure 13: Linearity (5µg/ml) Chromatogram

**Linearity 10 µg/ml**




Figure 14: Linearity (10µg/ml) Chromatogram

**Linearity 15µg/ml**




Figure 15: Linearity (15µg/ml) Chromatogram

**Linearity 20 µg/ml**



Figure 16: Linearity (20µg/ml) Chromatogram

**Linearity 25 µg/ml**




Figure 17: Linearity (25µg/ml) Chromatogram




Figure 18: Linearity of Pirfenidone

**Accuracy**




Figure 19: Chromatogram for Accuracy 50% recovery level

❖ Accuracy 100% Recovery level




Figure 20: Chromatogram for Accuracy 100% recovery level

Accuracy 150% Recovery level



Figure 21: Chromatogram for Accuracy 150% recovery level

Table 14: Accuracy Results

Recovery level	Concentration( $\mu\text{g/ml}$ )			Peak area n=3	%Mean Recovery
	Test (Initial amount)	Standard (Amount added)	Predicted Concentration		
50%	20 $\mu\text{g/ml}$	10 $\mu\text{g/ml}$	30 $\mu\text{g/ml}$	57520	101%
100%	20 $\mu\text{g/ml}$	20 $\mu\text{g/ml}$	40 $\mu\text{g/ml}$	71376	100%
150%	20 $\mu\text{g/ml}$	30 $\mu\text{g/ml}$	50 $\mu\text{g/ml}$	84516	98%

PRECISION

❖ Repeatability (Morning)




Figure 22: Precision Chromatogram of Standard Pirfenidone at 20  $\mu\text{g/ml}$

### Repeatability (Evening)



Figure 23: Precision Chromatogram of Standard Pirfenidone at 20 µg/ml

Table 15: Chromatogram results for Repeatability

Conc.20µg/ml Spikes	repeatability	Retention time(min)	Theoretical plates	Tailing factor
	Evening			
1	36069	4.98	5900.78	1.68
2	36012	4.94	5969	1.85
3	36115	4.95	5741	1.78
4	36541	4.95	5966	1.71
5	35899	4.97	5568	1.80
6	36140	4.98	5988	1.79

### ❖ Reproducibility (Day 1)

Table 16: Chromatogram results for Reproducibility

Conc.20µg/ml Spikes	repeatability	Retention time(min)	Theoretical plates	Tailing factor
	Day 1			
1	36060	4.98	5900	1.78
2	36012	4.94	5869	1.85
3	36105	4.95	5741	1.68
4	35987	4.95	5966	1.91
5	35899	4.97	5768	1.89
6	36014	4.98	5988	1.75

### Reproducibility (Day 2)




Figure 24: Precision Chromatogram of Standard Pirfenidone at 20 µg/ml

**Robustness:**

**Flow rate 0.8 ml/min**




Figure 25: Chromatogram for Robustness (Flow rate 0.8 ml/min)

**Flow rate 1.2 mL/min:**




Figure 26: Chromatogram for Robustness (Flow rate 1.2 ml/min)

Table 17: Robustness Results

Robustness		Flow rate 0.8ml/min		Flow rate 1.2ml/min	
Retention time = 4.97		Retention time	Peak area	Retention time	Peak area
Absorbance at 20µg/ml	S1	4.98	36060	4.92	36561
	S2	4.96	36115	4.91	36772
	S3	4.96	36899	4.93	35754
	S4	4.98	35879	4.93	36112
	S5	4.99	36174	4.92	36453
	S6	4.98	36172	4.91	36528
Mean ( n=6)		4.97	36216.5	4.975	36294.5
Standard deviation (SD)		0.01549193	351.65139	0.01378405	369.274288
RSD		0.00311709	0.0097097	0.00277066	0.01017439
%RSD		0.31%	0.97%	0.27%	1.01%

**Ruggedness**

❖ **Analyst-1**




Figure 27: Chromatogram for Ruggedness

## ❖ Analyst-2




Figure 28: Chromatogram for Ruggedness

Table 18: Ruggedness Results

Ruggedness		Analyst 1		Analyst 2	
		Retention time	Peak area	Retention time	Peak area
Absorbance at 20µg/ml	S1	4.95	36060	4.92	36151
	S2	4.94	36012	4.94	37015
	S3	4.94	36105	4.93	36001
	S4	4.97	36211	4.92	36060
	S5	4.96	35899	4.93	36200
	S6	4.95	36014	4.92	36001
Mean(n=6)		4.951666667	36050.17	4.926666667	36238
Standard deviation		0.01169045	157.7857	0.00816497	389.040872
RSD		0.00236091	0.00437	0.0016573	0.01073572
%RSD		0.23%	0.43%	0.16%	1.07%

## Limit of detection and Limit of quantification

Table 19: LOD &amp; LOQ

Limit of Detection	Limit of Quantification
0.05	0.15

- The  $\lambda_{max}$  of Pirfenidone in water was found to be 312nm. Water was used as a diluent. The drug exhibited the linearity in the concentration range of 1-10µg/ml with correlation coefficient of 0.999. The precision studies of the method revealed results of % R.S.D values less than 2% indicating that the developed method is precise. And the % recovery of the drug was found to be 98-102% by UV method.
- The RP-HPLC method show best results in terms of linearity, accuracy, precision, LOD, LOQ. Elution carried out using Methanol : water : Triethylamine (50:48.5:1.5%v/v).The linearity range was found to be 5-25µg/ml with correlation coefficient of 0.999 the percentage recovery was found to be 92%.

**CONCLUSION**

Literature survey indicates that the methods for the determination of

pirfenidone by RP-HPLC method were time consuming and costlier. So the present work aimed for the development of sensitive, economical and simpler methods for the estimation of pirfenidone in its pharmaceutical dosage forms.

A RP-HPLC method was developed using the mobile phase of 50:48.5:1.5 % v/v methanol and water and tri ethylamine. The run time of the developed method was six minutes, which reduces the solvent usage. The chromatographic conditions use ambient temperature which can yield accurate, precise results in the range of 25-35 °C. The results of the validation parameters showed that the method is accurate and precise.

Finally, it can be concluded that the methods for quantitation of pirfenidone by RP-HPLC Method in its pharmaceutical dosage forms can be applied for the routine analysis because of simplicity, accuracy, and preciseness.

**ACKNOWLEDGEMENT:** I thank SIMS College of Pharmacy for helping me through out the work, without which it may not be possible.

#### REFERENCES

- [1] Alisha P, Kesha D (2017) 'Method development and validation for

estimation of Pirfenidone by UV Spectrophotometric and RP-HPLC in tablet dosage form', International Journal of Pharmaceutical Research, 7 (3), pp.45-50.

- [2] Anusha R K, Devadasu Ch, Devala Rao G, Ravisankar P (2014) 'A novel validated RP-HPLC method for the determination of Pirfenidone in Pharmaceutical dosage form', Scholar's research library, pp.19-29.

- [3] Ashok P, Prabhakar S, Rina Mohan S, Snehal G (2018) 'Chromatographic method development and validation for estimation of Pirfenidone in pharmaceutical dosage form', European journal of biomedical and pharmaceutical science, 5(8), pp.552-558.

- [4] Atul A S, Chaudhari J, Pritham P, Mujeeb G K (2019) 'Development and validation of zero & first – order derivative area under curve spectrophotometric methods for the determination of pirfenidone in bulk material and pharmaceutical

- formulation', Asianj. Research Chem, volume 12(3), pp.129-135.
- [5] Audran M, Bromet P M, Brossolle F (1996) 'Validation of LC and GC methods application of pharmacokinetics', Journal of chromatography B, 6, pp.3- 11.
- [6] Azuma A, Ebina M, Kondoh Y, Raghu G, Taguchi Y, Takahashi H (2010) 'Pirfenidone in idiopathic pulmonary fibrosis', European respiratory journal, 35, pp.821-829.
- [7] Bockstaele E, Loose D, Taverniers I (2004) 'Trends in quality in the analytical laboratory, II. Analytical method validation and quality assurance', Trends Anal. Chem, 23, pp.535-552.
- [8] Chen Y, Liu X, Wang G, Wang Y, Zhao X, Zhong J (2006) 'Simple determination of pirfenidone in rat plasma via high-performance liquid chromatography', Biomed, 20, pp.1375-1379.
- [9] Dharmendra K, Sreedhar C, Sreenivasa R, Tamang R (2018) 'Analytical method development and validation for pirfenidone (Anti - fibrotic) in bulk drug and dosage form', International journal of chemistry and pharmaceutical sciences, 6(5), pp.134-140.
- [10] Desai S B, Parmar V K and Vaja T (2014) 'RP-HPLC and UV spectrophotometric methods for estimation of Pirfenidone in pharmaceutical formulation', Indian journal of Pharm science, 76(3), pp.225-229.
- [11] Feng Y, Zong G J, Zhan X (2009) 'Determination of Pirfenidone and its related substances', Anhui Medical and pharmaceutical journal, PP.15-25.
- [12] Hartmann C, Smeyers V, Massart R D (1998) 'Validation of bioanalytical chromatographic methods', Biomed, 17, pp. 193-218.
- [13] <http://www.intermune.com/Pirfenidone>.
- [14] <https://www.drugbank.ca/drugs/DB04951>.
- [15] <https://pubchem.ncbi.nlm.nih.gov/compound/pirfenidone>.
- [16] <https://www.drugdevelopmenttechnology.com/projects/pirfenidone-treatment-for-idiopathic-pulmonary-fibrosis>.

- [17] Ittadwar A M , Padmane S P, Tajne M R ,Thorat S G (2016) ‘Development and validation of simple, rapid and sensitive UV, HPLC and HPTLC methods for estimation of Pirfenidone in tablet dosage form’, Journal of the Chilean chemical society, 61(2), pp. 2978-2981.
- [18] Jiang H, Pan Y, Tong S., Wang X, Xuegu X (2010) ‘Determination of Pirfenidone in rat plasma by LC–MS-MS and its application to a pharmacokinetic study’, Chromatographia, 71, pp. 709-713.
- [19] Paul W, Noble (2016) “pirfenidone for idiopathic pulmonary fibrosis:analysis of pooled data from three multinational phase 3 trials”, Paul W. Noble, European Respiratory Journal, pp.243-253.
- [20] Siddhant M (2017) ‘Development of chromatographic method and validation for estimation of pirfenidone in bulk and pharmaceutical dosage form’, International research journal of pharmacy, 10(7), pp.45- 50.
- [21] Thorat S G, Rupesh V C (2016) ‘Determination and pharmacokinetic study of pirfenidone in rat serum by HPTLC’, Journal of chromatographic science, 54(7), pp.1115-1119.
- [22] Rowland M, Tozer T N (1995) ‘Clinical Pharmacokinetics Concepts and Applications’, United States of America, 3, pp.123-136.